DAT-2645
/ Danatlas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 17, 2026
A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
(clinicaltrials.gov)
- P2 | N=30 | Not yet recruiting | Sponsor: Danatlas Pharmaceuticals Co., Ltd
New P2 trial • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD
1 to 1
Of
1
Go to page
1